Since adhesion to the carcinoma matrix regulates NF-kB activity following treatment with cisplatin and overexpression of talin can control NF-kB activity it seemed possible that cisplatin treatment of talin overexpressing cells adherent to carcinoma matrix may influence nuclear NF-kB activity. The gene discussed is NFKB1; the disease is carcinoma.